青少年1型糖尿病患者达到范围内时间临床目标与治疗模式的关联
该多国队列研究纳入SWEET登记中21个国家、年龄小于21岁、病程至少6个月的1型糖尿病青少年5219例,比较间歇扫描式CGM或实时CGM联合或不联合胰岛素泵4种治疗模式与CGM临床目标达标比例的关系。校正性别、年龄、病程和BMI标准差评分后,实时CGM联合胰岛素泵组达到TIR>70%的比例最高(36.2%),其次为实时CGM联合注射(20.9%)、间歇扫描式CGM联合注射(12.5%)和间歇扫描式CGM联合胰岛素泵(11.3%)(P<.001)。实时CGM联合胰岛素泵组调整后TIR最高(64.7%),且治疗模式与严重低血糖和糖尿病酮症酸中毒事件的发生比例相关。作者认为,实时CGM联合胰岛素泵与更高的临床目标达标概率和更低的严重不良事件概率相关。
要点
- 校正性别、年龄、病程和BMI标准差评分后,实时CGM联合胰岛素泵组达到TIR>70%的比例为36.2%(95%CI 33.9%-38.4%),为4种模式中最高(P<.001)。
- 达到TIR>70%的比例:实时CGM联合注射20.9%(95%CI 18.0%-24.1%),间歇扫描式CGM联合注射12.5%(95%CI 10.7%-14.4%),间歇扫描式CGM联合胰岛素泵11.3%(95%CI 9.2%-13.8%)。
- 实时CGM联合胰岛素泵组调整后TIR为64.7%(95%CI 62.6%-66.7%),为各模式中最高。
- 达到TAR<25%的比例:实时CGM联合胰岛素泵32.5%(95%CI 30.4%-34.7%)vs 间歇扫描式CGM联合胰岛素泵12.8%(95%CI 10.6%-15.4%)(P<.001)。
- 达到TBR<4%的比例:实时CGM联合胰岛素泵73.1%(95%CI 71.1%-75.0%)vs 间歇扫描式CGM联合胰岛素泵47.6%(95%CI 44.1%-51.1%)(P<.001)。
适用人群与场景
- 年龄小于21岁的儿童、青少年和年轻成人1型糖尿病患者,病程至少6个月,提供2016年1月1日至2021年12月31日期间的CGM数据
- 来自国际SWEET登记,数据涵盖21个国家
诊断标准与关键阈值
- 推荐CGM临床目标:TIR>70%、TAR<25%、TBR<4%
研究设计与关键结果
- 多国队列研究,纳入5219例参与者(2714例[52.0%]男性;中位年龄14.4[IQR 11.2-17.1]岁),中位糖尿病病程5.2[IQR 2.7-8.7]年,中位血红蛋白A1c水平7.4%[IQR 6.8%-8.0%]
- 按治疗模式分为4组:间歇扫描式CGM联合或不联合胰岛素泵、实时CGM联合或不联合胰岛素泵
- 校正性别、年龄、糖尿病病程和BMI标准差评分后,达到TIR>70%目标的比例:实时CGM联合胰岛素泵36.2%(95%CI 33.9%-38.4%),实时CGM联合注射20.9%(95%CI 18.0%-24.1%),间歇扫描式CGM联合注射12.5%(95%CI 10.7%-14.4%),间歇扫描式CGM联合胰岛素泵11.3%(95%CI 9.2%-13.8%)(P<.001)
- 达到TAR<25%目标的比例:实时CGM联合胰岛素泵32.5%(95%CI 30.4%-34.7%),间歇扫描式CGM联合胰岛素泵12.8%(95%CI 10.6%-15.4%)(P<.001)
- 达到TBR<4%目标的比例:实时CGM联合胰岛素泵73.1%(95%CI 71.1%-75.0%),间歇扫描式CGM联合胰岛素泵47.6%(95%CI 44.1%-51.1%)(P<.001)
- 调整后TIR在实时CGM联合胰岛素泵使用者中最高(64.7%[95%CI 62.6%-66.7%])
- 治疗模式与发生严重低血糖和糖尿病酮症酸中毒事件的比例相关
证据类型、等级与局限
- 证据类型:多国队列研究
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,在1型糖尿病青少年中,同时使用实时CGM和胰岛素泵与其他治疗模式相比,与达到推荐临床目标和TIR目标的概率增加以及严重不良事件概率降低相关
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Continuous glucose monitoring (CGM) devices have demonstrated efficacy in adults and more recently in youths and older adults with type 1 diabetes. In adults with type 1 diabetes, the use of real-time CGM compared with intermittently scanned CGM was associated with improved glycemic control, but there are limited data available for youths.
OBJECTIVE: To assess real-world data on achievement of time in range clinical targets associated with different treatment modalities in youths with type 1 diabetes.
DESIGN, SETTING, AND PARTICIPANTS: This multinational cohort study included children, adolescents, and young adults younger than 21 years (hereinafter referred to collectively as youths) with type 1 diabetes for a duration of at least 6 months who provided CGM data between January 1, 2016, and December 31, 2021. Participants were enrolled from the international Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) registry. Data from 21 countries were included. Participants were divided into 4 treatment modalities: intermittently scanned CGM with or without insulin pump use and real-time CGM with or without insulin pump use.
EXPOSURES: Type 1 diabetes and the use of CGM with or without an insulin pump.
MAIN OUTCOMES AND MEASURES: Proportion of individuals in each treatment modality group achieving recommended CGM clinical targets.
RESULTS: Among the 5219 participants (2714 [52.0%] male; median age, 14.4 [IQR, 11.2-17.1] years), median duration of diabetes was 5.2 (IQR, 2.7-8.7) years and median hemoglobin A1c level was 7.4% (IQR, 6.8%-8.0%). Treatment modality was associated with the proportion of individuals achieving recommended clinical targets. Adjusted for sex, age, diabetes duration, and body mass index standard deviation score, the proportion achieving the recommended greater than 70% time in range target was highest with real-time CGM plus insulin pump use (36.2% [95% CI, 33.9%-38.4%]), followed by real-time CGM plus injection use (20.9% [95% CI, 18.0%-24.1%]), intermittently scanned CGM plus injection use (12.5% [95% CI, 10.7%-14.4%]), and intermittently scanned CGM plus insulin pump use (11.3% [95% CI, 9.2%-13.8%]) (P < .001). Similar trends were observed for less than 25% time above (real-time CGM plus insulin pump, 32.5% [95% CI, 30.4%-34.7%]; intermittently scanned CGM plus insulin pump, 12.8% [95% CI, 10.6%-15.4%]; P < .001) and less than 4% time below range target (real-time CGM plus insulin pump, 73.1% [95% CI, 71.1%-75.0%]; intermittently scanned CGM plus insulin pump, 47.6% [95% CI, 44.1%-51.1%]; P < .001). Adjusted time in range was highest among real-time CGM plus insulin pump users (64.7% [95% CI, 62.6%-66.7%]). Treatment modality was associated with the proportion of participants experiencing severe hypoglycemia and diabetic ketoacidosis events.
CONCLUSIONS AND RELEVANCE: In this multinational cohort study of youths with type 1 diabetes, concurrent use of real-time CGM and an insulin pump was associated with increased probability of achieving recommended clinical targets and time in range target as well as lower probability of severe adverse events compared with other treatment modalities.
参考来源
- Dovc K, Lanzinger S, Cardona-Hernandez R, et al. Association of Achieving Time in Range Clinical Targets With Treatment Modality Among Youths With Type 1 Diabetes. JAMA Netw Open. 2023. PMID: 36808243. doi:10.1001/jamanetworkopen.2023.0077
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。